Normally, the amount of CB1R is low in liver tissue [56]; however, under pathological conditions, the expression of CB1R in hepatic cells increases, thus contributing to hepatic insulin resistance, fibrosis, lipogenesis, and steatosis [53]. Here, INS is linked to steatosis.